AbbVie has introduced Epcoritamab (epkinly®/tepkinly®) for the treatment of relapsed/refractory follicular lymphoma.
Epcoritamab is an investigational IgG1-bispecific antibody developed using Genmab's DuoBody® technology.
Genmab's DuoBody-CD3 technology is engineered to facilitate the selective activation of cytotoxic T cells, prompting an immune response against specific target cell types. Epcoritamab, utilising this technology, is precisely designed to engage with both CD3 on T cells and CD20 on B cells simultaneously.
This dual binding mechanism aims to trigger T-cell-mediated destruction of CD20+ cells, thereby directing the immune system to eliminate B cells marked for destruction due to conditions like relapsed or refractory follicular lymphoma.
Epcoritamab, also known as EPKINLY, is an investigational therapy for relapsed or refractory B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma. It was being studied for its potential to treat these specific types of lymphomas in patients who had not responded to prior treatments or had relapsed after receiving two or more therapies.
Epcoritamab has received global regulatory approval under the brand names EPKINLY® and TEPKINLY® for treating certain types of large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) in the United States and in the European Union.
Epcoritamab-bysp, marketed as EPKINLY®, received breakthrough therapy designation (BTD) from the FDA for treating adult patients with relapsed or refractory follicular lymphoma (R/R FL) who have undergone two or more prior therapies.
